IP Library Granted Patent US 7,045,600
Granted Patent B2
US 7,045,600 · App. 10/184,372 · Granted May 16, 2006

Modification of collagenous materials and medical treatment, diagnosis and monitoring of fibrotic conditions

Assignee: Nederlandse Organisatie voor Toegepastnatuur-Wetenschappelijk Ondrezoek TNO
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,045,600
App. No.
10/184,372
Granted
May 16, 2006
Kind
B2
Abstract

The present invention relates to the gene PLOD2 which codes for telopeptide lysyl hydroxylase (TLH). This enzyme converts telopeptidyl Lys into telopeptidyl Hyl, that can subsequently be converted into hydroxyallysine cross-links. Collagen with hydroxyallysine cross-links shows a higher resistance to degradation by proteinases than collagen with cross-links derived from allysine. In one aspect, the invention provides methods and compositions to prepare collagenous materials with varying biodegradation rates by varying the ratio of hydroxyallysine cross-links over allysine cross-links. In another aspect, the invention provides methods and compositions to lower the ratio of hydroxyallysine cross-links over allysine cross-links in fibrotic processes, in order to obtain a collagenous network that is more easy to degrade. Furthermore, the invention provides methods to diagnose and/or monitor fibrotic processes by measuring mRNA levels of PLOD2, by measuring protein levels of the translated mRNA, and/or by measuring enzymatic activity levels of TLH. The invention also provides the description of a high through-put system facilitating the screening of antagonists of telopeptide lysyl hydroxylase.

Claims (14)

1. A method for obtaining an ex vivo collagenous matrix which comprises cross-linked collagen molecules by controlling the ratio of hydroxyallysine cross-links to allysine cross-links in the ex vivo collagenous matrix, thereby controlling the resistance of said collagenous matrix against proteolytic degradation.

2. The method of claim 1 wherein the ratio of hydroxyallysine cross-links to allysine cross-links in the collagenous matrix is controlled by controlling the lysyl hydroxylation level of the collagen telopeptides.

3. The method of claim 2 wherein the lysyl hydroxylation level of the collagen telopeptides is controlled by controlling the level of telopeptide lysyl hydroxylase activity.

4. The method of claim 3 wherein the level of telopeptide lysyl hydroxylase activity is controlled by controlling the expression of a PLOD2 gene or by controlling the telopeptide lysyl hydroxylase activity of a PLOD2 expression product.

5. The method of claim 1 comprising obtaining collagen from tissues which show an increased ratio of hydroxyallysine cross-links to allysine cross-links and using said collagen to prepare a collagenous matrix with an increased resistance against proteolytic degradation.

6. The method of claim 1 comprising obtaining collagen from tissues which predominantly show allysine cross-links and using said collagen for preparing a collagenous matrix, wherein a collagenous matrix with an increased resistance against proteolytic degradation is obtained by admixing collagen obtained from tissues which show an increased ratio of hydroxyallysine cross-links to allysine cross-links and using said collagen to prepare a collagenous matrix with an increased resistance against proteolytic degradation.

7. The method of claim 1 comprising culturing cells producing collagen with telopeptides having an increased ratio of hydroxylysine to lysine residues and using the collagen produced for preparing a collagenous matrix having an increased resistance against proteolytic degradation due to an increased ratio of hydroxyallysine cross-links to allysine cross-links.

8. The method of claim 7 wherein said collagen-producing cells comprise a recombinant, constitutively expressed PLOD2 gene.

9. The method of claim 7 wherein said collagen-producing cells are cultured in the presence of a composition which stimulates the expression of a PLOD2 gene.

10. The method of claim 1 comprising obtaining collagen from tissues which show a decreased ratio of hydroxyallysine cross-links to allysine cross-links and using said collagen to prepare a collagenous matrix with a decreased resistance against proteolytic degradation.

11. The method of claim 1 comprising obtaining collagen from tissues which predominantly show hydroxyallysine cross-links and using said collagen for preparing a collagenous matrix, wherein a collagenous matrix with a decreased resistance against proteolytic degradation is obtained by admixing collagen obtained from tissues which show a decreased ratio of hydroxyallysine cross-links to allysine cross-links and using said collagen to prepare a collagenous matrix with a decreased resistance against proteolytic degradation.

12. The method of claim 1 comprising culturing cells producing collagen with telopeptides having a decreased ratio of hydroxylysine to lysine residues and using the collagen produced for preparing a collagenous matrix having a decreased resistance against proteolytic degradation due to a decreased ratio of hydroxyallysine cross-links to allysine cross-links.

13. The method of claim 12 wherein said collagen-producing cells are cultured in the presence of a composition which inhibits the activity or production of PLOD2-encoded telopeptide lysyl hydroxylase.

14. The method of claim 13 wherein said composition does not affect the level of lysyl oxidase.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 30, 2017
From: SHIRE HUMAN GENETIC THERAPIES, INC.; LOTUS TISSUE REPAIR, INC.
To: PHOENIX TISSUE REPAIR, INC.
Reel/Frame 043447/0805 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 18, 2014
From: NEDERLANDSE ORGANISATIE VOOR TOEGEPAST-NATUURWETENSCHAPPELIJKONDERZOEK TNO
To: SHIRE HUMAN GENETIC THERAPIES, INC.
Reel/Frame 033766/0117 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 15, 2002
From: BANK, RUDOLF ANTONIUS; VAN DER SLOT, ANNEMARIE JOZEFIEN; KOPPELE, JOHANNES MARIA TE
To: NEDERLANDSE ORGANISATIE VOOR TOEGEPASTNATUUR- WETENSCHAPPELIJK ONDERZOEK TNO
Reel/Frame 013383/0775 →
Continuity (2)
Continuation In Part 0945020900 · Nov 29, 1999
Related Publication 20030219852A1 · Nov 27, 2003